CY1122374T1 - Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων - Google Patents

Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων

Info

Publication number
CY1122374T1
CY1122374T1 CY20191101195T CY191101195T CY1122374T1 CY 1122374 T1 CY1122374 T1 CY 1122374T1 CY 20191101195 T CY20191101195 T CY 20191101195T CY 191101195 T CY191101195 T CY 191101195T CY 1122374 T1 CY1122374 T1 CY 1122374T1
Authority
CY
Cyprus
Prior art keywords
biotin
neuropathies
demyelinotic
therapeutic treatment
treatment
Prior art date
Application number
CY20191101195T
Other languages
English (en)
Inventor
Frédéric SEDEL
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122374(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of CY1122374T1 publication Critical patent/CY1122374T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Η εφεύρεση σχετίζεται με τη χρήση της βιοτίνης για την θεραπευτική αντιμετώπιση της Αμυοτροφικής Πλευρικής Σκλήρυνσης, καθώς και απομυελινωτικών περιφερικών νευροπαθειών και της Οπτικής Νευρομυελίτιδας (ΝΜΟ).
CY20191101195T 2015-03-26 2019-11-13 Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων CY1122374T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305437.4A EP3072513A1 (en) 2015-03-26 2015-03-26 Biotin for treating Amyotrophic lateral sclerosis
PCT/EP2016/056696 WO2016151132A1 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
CY1122374T1 true CY1122374T1 (el) 2021-01-27

Family

ID=52779582

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101195T CY1122374T1 (el) 2015-03-26 2019-11-13 Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων

Country Status (23)

Country Link
US (2) US10357480B2 (el)
EP (2) EP3072513A1 (el)
JP (1) JP6752874B2 (el)
KR (1) KR20170131543A (el)
CN (2) CN107405335A (el)
AU (1) AU2016238759B2 (el)
BR (1) BR112017020408A2 (el)
CA (1) CA2980660A1 (el)
CY (1) CY1122374T1 (el)
DK (1) DK3273957T3 (el)
EA (1) EA034394B1 (el)
ES (1) ES2748354T3 (el)
HR (1) HRP20191491T1 (el)
HU (1) HUE046116T2 (el)
IL (1) IL254619B (el)
LT (1) LT3273957T (el)
MA (1) MA41809B1 (el)
ME (1) ME03567B (el)
PL (1) PL3273957T3 (el)
PT (1) PT3273957T (el)
RS (1) RS59149B1 (el)
SI (1) SI3273957T1 (el)
WO (1) WO2016151132A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
GEP20094699B (en) 2002-09-27 2009-06-10 Biogen Idec Inc THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING ß-INTERFERON
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
AU2012245205B2 (en) * 2011-04-21 2017-06-01 The Regents Of The University Of California, A California Corporation Compositions and methods for the treatment of neuromyelitis optica
EA028060B1 (ru) * 2011-07-13 2017-10-31 Сайтокинетикс, Инк. Комбинированная терапия бокового амиотрофического склероза
CA2910717C (en) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
US20190314342A1 (en) 2019-10-17
HRP20191491T1 (hr) 2019-11-15
US10357480B2 (en) 2019-07-23
SI3273957T1 (sl) 2019-11-29
EP3273957B1 (en) 2019-08-14
IL254619A0 (en) 2017-11-30
EA201792124A1 (ru) 2018-04-30
MA41809B1 (fr) 2019-12-31
ES2748354T3 (es) 2020-03-16
PL3273957T3 (pl) 2020-01-31
IL254619B (en) 2020-03-31
PT3273957T (pt) 2019-09-18
JP6752874B2 (ja) 2020-09-09
EP3072513A1 (en) 2016-09-28
LT3273957T (lt) 2019-11-11
JP2018512451A (ja) 2018-05-17
MA41809A (fr) 2018-01-30
EP3273957A1 (en) 2018-01-31
CN111973592A (zh) 2020-11-24
ME03567B (me) 2020-07-20
BR112017020408A2 (pt) 2018-06-05
US20180125825A1 (en) 2018-05-10
AU2016238759B2 (en) 2020-08-06
WO2016151132A1 (en) 2016-09-29
CA2980660A1 (en) 2016-09-29
RS59149B1 (sr) 2019-09-30
EA034394B1 (ru) 2020-02-04
KR20170131543A (ko) 2017-11-29
HUE046116T2 (hu) 2020-02-28
AU2016238759A1 (en) 2017-10-05
CN107405335A (zh) 2017-11-28
DK3273957T3 (da) 2019-11-11
NZ735528A (en) 2021-09-24

Similar Documents

Publication Publication Date Title
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1121182T1 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CY1123417T1 (el) Παραγωγα τετρα�δροϊσοκινολινης
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
EA201890204A1 (ru) Антибактериальные соединения
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CY1125047T1 (el) Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA202090683A3 (ru) Способы и композиции для лечения рака
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201791174A1 (ru) Антимикотическое соединение
CY1122374T1 (el) Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
CY1125031T1 (el) Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose